Protagonist Therapeutics (PTGX) Stock Chart & Stock Price History $57.48 +1.44 (+2.57%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$57.48 +0.01 (+0.01%) As of 08/22/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Protagonist Therapeutics Stock Price Performance The Protagonist Therapeutics (PTGX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 37.91%, with a year-to-date return of 48.91%. In the past month, the stock has increased 6.07%, reflecting recent market activity. As of the latest close, Protagonist Therapeutics traded at $57.48 with a market cap of $3.58 billion and volume of 470,129 shares. Five years ago, the stock traded at $20.98, representing a 173.98% increase over that period. At the time, it had a market cap of $722.16 million and a volume of 305,400 shares. Receive PTGX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+2.26%1 Month Performance+6.07%3 Month Performance+25.89%Year-To-Date Performance+48.91%1 Year Performance+37.91%5 Year Performance+173.98% PTGX Stock Chart for Saturday, August, 23, 2025 PTGX Chart by TradingView Protagonist Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$56.04$57.48+2.57%$57.72$56.10470,129 shs$3.58 billion08/21/2025$56.23$56.04-0.34%$56.47$55.26500,857 shs$3.49 billion08/20/2025$56.25$56.23-0.04%$57.10$55.27675,235 shs$3.50 billion08/19/2025$56.21$56.25+0.07%$56.56$55.26528,400 shs$3.50 billion08/18/2025$56.07$56.21+0.25%$57.99$55.51470,840 shs$3.50 billion08/15/2025$54.99$56.07+1.96%$56.33$54.18471,864 shs$3.49 billion08/14/2025$56.72$54.99-3.05%$56.58$54.96615,071 shs$3.42 billion08/13/2025$54.53$56.72+4.02%$56.85$54.57999,381 shs$3.53 billion08/12/2025$53.75$54.53+1.45%$54.74$53.49541,716 shs$3.39 billion08/11/2025$51.07$53.75+5.25%$53.80$50.58866,488 shs$3.34 billion Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$50.96$51.07+0.22%$51.41$50.49719,043 shs$3.17 billion08/07/2025$53.82$50.96-5.32%$54.81$50.76901,193 shs$3.16 billion08/06/2025$53.90$53.82-0.15%$54.37$52.11449,055 shs$3.34 billion08/05/2025$53.83$53.90+0.13%$54.33$52.03460,669 shs$3.34 billion08/04/2025$53.83$53.83$54.17$52.18373,998 shs$3.34 billion08/01/2025$53.86$53.83-0.06%$55.49$53.60600,772 shs$3.34 billion07/31/2025$54.62$53.86-1.39%$55.29$53.69561,129 shs$3.34 billion07/30/2025$55.01$54.62-0.71%$56.31$54.07388,819 shs$3.39 billion07/29/2025$56.26$55.01-2.22%$57.15$54.53802,688 shs$3.41 billion07/28/2025$55.15$56.26+2.01%$57.10$55.21681,184 shs$3.49 billion07/25/2025$53.74$55.15+2.62%$55.25$53.06490,995 shs$3.42 billion07/24/2025$54.19$53.74-0.83%$54.70$53.56695,927 shs$3.33 billion07/23/2025$54.99$54.19-1.45%$55.02$51.551.31 million shs$3.36 billion07/22/2025$55.22$54.99-0.42%$55.26$54.28680,283 shs$3.41 billion Related Companies Viatris Stock Price Chart Ascendis Pharma A/S Stock Price Chart Dr. Reddy's Laboratories Stock Price Chart QIAGEN Stock Price Chart Moderna Stock Price Chart BridgeBio Pharma Stock Price Chart Verona Pharma PLC American Depositary Share Stock Price Chart Elanco Animal Health Stock Price Chart Blueprint Medicines Stock Price Chart Roivant Sciences Stock Price Chart Receive PTGX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PTGX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access